US FDA orders new eye risk warnings for Ozempic, Zepbound
NVO•The FDA is requiring GLP-1 drugs including Ozempic, Zepbound, Mounjaro and Wegovy to add warnings about a potential increased risk of NAION, a common cause of sudden, painless vision loss.
1. New labeling requirement
The FDA said it is requiring GLP-1 drugs used for weight loss and diabetes, including Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy, to add information about the potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to the “warnings and precautions” section of their labeling.
2. Eye condition
The FDA informed patients and healthcare providers of the potential risk. NAION is a common cause of sudden, painless vision loss.
